Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

The MS-LINK™ Outcomes Study

NCT04735406 · View on ClinicalTrials.gov ↗

Study Summary

The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction from the participant's electronic medical record (EMR) and other health information systems (for example, radiology). Participants will complete patient-reported outcomes (PROs) and other health-related information digitally. Participating participants will have access to their own data in an ongoing manner via a web-based Participant Portal.

Conditions Studied

Study Locations (9)

Texas

  • The University of Texas of Austin — Austin
  • University of Texas Health — San Antonio

Alabama

  • Alabama Neurology Associates — Birmingham

District of Columbia

  • Georgetown University — Washington D.C.

Georgia

  • Atlanta Neuroscience Institute — Atlanta

Massachusetts

  • Beth Israel Deaconess Medical Center — Boston

Michigan

  • Memorial healthcare — Owosso

Nebraska

  • University of Nebraska medical Center — Omaha

Oklahoma

  • The Oklahoma Medical Research Foundation — Oklahoma City

Trial Details

FieldValue
Enrollment Target 2,182 participants
Start Date 2021-03-24
Est. Completion 2024-05-31

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04735406

The ClinicalTrials.gov registry entry for NCT04735406 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04735406 reports 9 study locations spanning 8 distinct geographic areas — top geographies include Texas, Alabama, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04735406 about?

NCT04735406 is a clinical study titled "The MS-LINK™ Outcomes Study". The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the stu...

What is the current status of trial NCT04735406?

This trial is currently completed. The enrollment target is 2,182 participants. The study started on 2021-03-24. Estimated completion is 2024-05-31.

What conditions does trial NCT04735406 study?

This clinical trial studies the following conditions: Multiple Sclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT04735406?

This trial is sponsored by EMD Serono Research & Development Institute, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04735406 being conducted?

This trial has 9 study locations across Alabama, District of Columbia, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial